Researchers Slow Alzheimer's, Improve Memory In Mice Using Novel Drug
Brett Smith for redOrbit.com - Your Universe Online Many Alzheimer’s disease researchers are focused on stopping the buildup of amyloid plaques, dense protein deposits that are a telltale sign of the debilitating disease. However, a group of...
Latest Rare diseases Stories
America's brave men and women in uniform are more likely to die from ALS than any other segment of the U.S. population WASHINGTON, May 23, 2013 /PRNewswire-USNewswire/ -- The ALS Association joins the nation this Memorial Day to remember all of the men and women who died while serving in the U.S. military. During May, ALS Awareness Month, The ALS Association is also paying tribute to veterans like retired Air Force Technical Sergeant David Masters of Omaha, Nebraska, who fought...
The Multiple System Atrophy Coalition launches its new MSA Research Grant program, including the creation of a world-class Scientific Advisory Board and Advocate Research Committee to review research proposals and recommend grants. Raleigh, NC (PRWEB) May 20, 2013 The Multiple System Atrophy Coalition (formerly the SDS/MSA Support Group) announced today the launch of its new Multiple System Atrophy (MSA) Research Grant Program. Over the past few years, The MSA Coalition’s grass roots...
Data Shows, Early Stem Cell Transplantation Could Slow Progression Or Even Improve Patient's Condition in Some Forms of ALS ROCKVILLE, Md., May 20, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today reported that Eva Feldman, MD, PhD, principal investigator, presented updated Phase I data from its spinal cord-derived human neural stem cell (NSI-566) trial in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) at the neuro diabetes special...
A leader in herbal medicine, Neuracel has launched its latest product the Ultimate Neuropathy Support System. With its latest creation, the company hopes to provide an effective treatment for those suffering from peripheral neuropathy on http://www.neuracel.com. Boise, Idaho (PRWEB) May 19, 2013 The muscles in the human body are dependent on various nerves for their functionality and one of the biggest and most significant nervous systems in the body is the peripheral nervous system. The...
AWARD RECOGNIZES MEDICAL INNOVATION OF CYSTARAN(TM) GAITHERSBURG, Md., May 15, 2013 /PRNewswire/ -- Sigma-Tau Pharmaceuticals, Inc. announced today that the Company was recognized last evening as a rare disease pioneer at the 30(th) anniversary celebration of The National Organization for Rare Disorders (NORD). During the event, Sigma-Tau received an innovation award for the development of CYSTARAN(TM) (cysteamine ophthalmic solution) 0.44% -- the first and only approved therapy...
Local events planned throughout May to highlight MDA's ALS Awareness Month campaign. Monroe, LA (PRWEB) May 14, 2013 May is national ALS Awareness Month, and the Ark-La-Tex Chapter of the Muscular Dystrophy Association will commemorate the 22nd campaign with local ALS Awareness Month activities and events. ALS (amyotrophic lateral sclerosis, or Lou Gehrig’s disease) attacks the nerve cells that control voluntary muscles, including those used for swallowing and breathing, causing...
DOYLESTOWN, Pa., May 14, 2013 /PRNewswire/ -- Callidus Biopharma, Inc., a development-stage biotechnology company focused on creating breakthrough biologic drugs for a range of orphan diseases, announced today that it has closed on $4.6 million in Series A financing led by two strategic investors. The Company intends to use the proceeds to accelerate pre-clinical development of its drug discovery pipeline of therapies for lysosomal storage diseases (LSDs), including lead candidates...
CAMBRIDGE, Mass., May 14, 2013 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) announced today that 38 microbrewers across the country have joined the Ales for ALS campaign in support of ALS TDI's mission to discover and develop effective treatments for ALS, commonly known as Lou Gehrig's disease. Ales for ALS(TM) is a unique craft brewery-based fundraising initiative created to accelerate drug development for ALS patients today. (Logo:...
30th Anniversary Gala to honor rare disease heroes and support the continuation of NORD's critical work on behalf of the rare disease community WASHINGTON, May 10, 2013 /PRNewswire-USNewswire/ -- The 30(th) Anniversary Gala of the National Organization for Rare Disorders (NORD), to be held Tuesday, May 14, 2013, will honor rare disease heroes, celebrate 30 years of progress through the Orphan Drug Act (ODA) and NORD, and promote a promising future for the rare disease community....
Researchers at Georgetown University Medical Center have used tiny doses of a leukemia drug to halt accumulation of toxic proteins linked to Parkinson's disease in the brains of mice. This finding provides the basis to plan a clinical trial in humans to study the effects. They say their study, published online May 10 in Human Molecular Genetics, offers a unique and exciting strategy to treat neurodegenerative diseases that feature abnormal buildup of proteins in Parkinson's disease,...
